Windtree's phase 2 shock med rapidly raises blood pressure—and share price

Windtree's phase 2 shock med rapidly raises blood pressure—and share price

Source: 
Fierce Biotech
snippet: 

Windtree Therapeutics’ cardiogenic shock medicine istaroxime rapidly raised systolic blood pressure in patients with the life-threatening condition, meeting the main goal of a phase 2 study and sending the small biotech’s shares climbing nearly 40% as the markets opened Wednesday.